Metabolomic analysis of a selective ABCA1 inducer in obesogenic challenge provides a rationale for therapeutic development

Metabolomic analysis of a selective ABCA1 inducer in obesogenic challenge provides a rationale for therapeutic development

Background: Therapeutic agents with novel mechanisms of action are needed to combat the growing epidemic of type 2 diabetes (T2D) and related metabolic syndromes. Liver X receptor (LXR) agonists possess preclinical efficacy yet produce side effects due to excessive lipogenesis. Anticipating that man...

Full description

Bibliographic Details
Main Authors: Cutler T. Lewandowski, Md.Wasim Khan, Manel BenAissa, Oleksii Dubrovskyi, Martha Ackerman-Berrier, Mary Jo LaDu, Brian T. Layden, Gregory R.J. Thatcher
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:EBioMedicine
Subjects:
ABCA1
Anti-inflammatory
Drug discovery
High-fat diet
Metabolomics
Type 2 diabetes
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421000803

Similar Items

Similar Items